NFE2L2 and non-small cell lung carcinoma: In another study, atezolizumab-treated NSCLC patients with KEAP1/NFE2L2 mutations had significantly poorer OS compared to patients with wild type KEAP1/NFE2L2 (HR = 1.97, 95% CI = 1.48–2.63, p < 0.001) [88].